HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Bronchodilator Agents (Bronchodilators)

Agents that cause an increase in the expansion of a bronchus or bronchial tubes.
Also Known As:
Bronchodilators; Broncholytic Agents; Agents, Bronchial-Dilating; Agents, Bronchodilator; Agents, Broncholytic; Bronchial Dilating Agents; Bronchial-Dilating Agents
Networked: 2115 relevant articles (191 outcomes, 228 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Cazzola, Mario: 31 articles (09/2015 - 01/2004)
2. Matera, Maria Gabriella: 15 articles (09/2015 - 01/2004)
3. Hanania, Nicola A: 14 articles (01/2015 - 05/2005)
4. Donohue, James F: 12 articles (08/2015 - 08/2004)
5. Barnes, Peter J: 11 articles (09/2015 - 09/2002)
6. Tashkin, Donald P: 11 articles (01/2014 - 08/2003)
7. Ulrik, Charlotte Suppli: 10 articles (12/2015 - 01/2006)
8. Fabbri, Leonardo M: 10 articles (02/2015 - 01/2003)
9. O'Donnell, Denis E: 9 articles (01/2015 - 05/2003)
10. Calverley, Peter M A: 9 articles (10/2014 - 05/2006)

Related Diseases

1. Chronic Obstructive Pulmonary Disease (COPD)
01/01/2014 - "All guidelines recommend bronchodilators as baseline therapy for all stages of COPD, and long-acting inhaled bronchodilators, both beta-2 agonist (LABA) and antimuscarinic (LAMA) drugs, are the most effective in regular treatment in the clinically stable phase. "
08/01/2000 - "However, since physicians must always choose a drug that is highly efficacious, well tolerated and inexpensive, the cost-effectiveness analysis in relation to other bronchodilators will determine the proper place of long-acting beta2 agonists in the long term therapy of stable COPD."
01/01/2013 - "An increasing body of evidence suggests that the long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA) combination appears to play an important role in maximizing bronchodilation, with studies to date indicating that combining different classes of bronchodilators may result in significantly greater improvements in lung function compared to the use of a single drug, and that these combinations are well tolerated in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). "
10/01/2013 - "Novel once-daily dosing bronchodilators, such as the long-acting muscarinic antagonist (LAMA) glycopyrronium and the LAMA/long-acting β2-agonist (LABA) fixed-dose combination QVA149, have been shown to provide significant benefits to patients with COPD in terms of improvement in lung function, exercise tolerance, health-related quality of life, symptoms and reduction in the rate of exacerbations. "
11/01/2007 - "Combining bronchodilators has been shown to be beneficial in patients with COPD. "
2. Asthma (Bronchial Asthma)
3. Obstructive Lung Diseases (Obstructive Lung Disease)
4. Bronchiolitis
5. Respiratory Sounds (Crackle)

Related Drugs and Biologics

1. Adrenal Cortex Hormones (Corticosteroids)
2. Steroids
3. Albuterol (Salbutamol)
4. 5- (2- (5,6- diethylindan- 2- ylamino)- 1- hydroxyethyl)- 8- hydroxy- 1H- quinolin- 2- one
5. Nedocromil (Alocril)
6. Oxygen
7. Epinephrine (Adrenaline)
8. Theophylline (Theon)
9. tiotropium (Spiriva)
10. salmeterol (Serevent)

Related Therapies and Procedures

1. Nebulizers and Vaporizers (Inhaler)
2. Artificial Respiration (Mechanical Ventilation)
3. Metered Dose Inhalers (Metered Dose Inhaler)
4. Drug Therapy (Chemotherapy)
5. Aftercare (After-Treatment)